Morphosys Stock Price, News & Analysis (ETR:MOR)

€80.52 2.12 (2.70 %)
(As of 12/11/2017 01:49 AM ET)
Previous Close€78.40
Today's Range€79.07 - €80.77
52-Week Range€42.56 - €83.83
Volume107,325 shs
Average Volume169,282 shs
Market Capitalization$2.36 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A

About Morphosys (ETR:MOR)

Morphosys logoMorphoSys AG, together with its subsidiaries, engages in the research, development, and optimization of therapeutic antibody drug candidates in partnerships with pharmaceutical and biotechnology companies. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 100 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation. Its product pipeline includes MOR208, a humanized monoclonal antibody that targets the antigen CD19, which is in Phase II clinical trials for the treatment of B cell malignancies; and MOR202, a human monoclonal HuCAL-antibody directed against CD38, which is in Phase I/IIa trials for the treatment of multiple myeloma and various leukemias. The company’s product pipeline also comprises MOR103, a human HuCAL-antibody directed against granulocyte-macrophage colony-stimulating factor that is in Phase II clinical trials for treating rheumatoid arthritis; and MOR209/ES414, a bi-specific anti-PSMA/anti-CD3 antibody against prostate cancer that is in Phase I clinical trials for the treatment of metastatic castration-resistant prostate cancer. In addition, its product pipeline includes MOR106, a human monoclonal IL-17C antibody, which is in Phase I clinical trials for the treatment of atopic dermatitis; and MOR107, a novel lanthipeptide that is in Phase I clinical trials for the treatment of fibrotic diseases. The company was founded in 1992 and is headquartered in Planegg, Germany.

Receive MOR News and Ratings via Email

Sign-up to receive the latest news and ratings for MOR and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
SymbolETR:MOR
CUSIPN/A
Phone+49-89-899270

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

Trailing EPS(€2.95)
Net IncomeN/A
Net Margins-159.62%
Return on Equity-25.28%
Return on Assets-22.11%

Miscellaneous

EmployeesN/A
Outstanding Shares29,010,000

Morphosys (ETR:MOR) Frequently Asked Questions

What is Morphosys' stock symbol?

Morphosys trades on the ETR under the ticker symbol "MOR."

Where is Morphosys' stock going? Where will Morphosys' stock price be in 2017?

7 brokerages have issued 12 month price objectives for Morphosys' stock. Their forecasts range from €76.00 to €93.00. On average, they expect Morphosys' stock price to reach €85.57 in the next year. View Analyst Ratings for Morphosys.

Who are some of Morphosys' key competitors?

Who are Morphosys' key executives?

Morphosys' management team includes the folowing people:

  • Gerald Moeller, Chairman of the Supervisory Board
  • Simon E. Moroney Ph.D., Member of the Management Board, Chief Executive Officer
  • Jens Holstein, Chief Financial Officer, Member of the Management Board
  • Markus Enzelberger, Chief Scientific Officer, Member of the Management Board
  • Anke Linnartz, Vice President and Head of Corporate Communications and Investor Relations
  • Malte Peters, Chief Development Officer , Member of the Management Board
  • Marc Cluzel M.D., Ph.D., Member of the Supervisory Board (Age 57)
  • Karin Eastham CPA, Member of the Supervisory Board (Age 67)
  • Wendy Johnson, Member of the Supervisory Board
  • Klaus Kuehn, Member of the Supervisory Board

What is Morphosys' stock price today?

One share of Morphosys stock can currently be purchased for approximately €80.52.

How big of a company is Morphosys?

Morphosys has a market capitalization of $2.36 billion.

How can I contact Morphosys?

Morphosys' mailing address is Semmelweisstr. 7, PLANEGG, 82152, Germany. The company can be reached via phone at +49-89-899270.


MarketBeat Community Rating for Morphosys (MOR)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  84 (Vote Outperform)
Underperform Votes:  54 (Vote Underperform)
Total Votes:  138
MarketBeat's community ratings are surveys of what our community members think about Morphosys and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Morphosys (ETR:MOR) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.862.862.712.75
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: €85.57€84.43€72.00€69.00

Morphosys (ETR:MOR) Consensus Price Target History

Price Target History for Morphosys (ETR:MOR)

Morphosys (ETR:MOR) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetDetails
12/7/2017Berenberg BankSet Price TargetBuy€85.00View Rating Details
12/1/2017Independent ResearchSet Price TargetBuy€93.00View Rating Details
11/27/2017Goldman Sachs GroupSet Price TargetNeutral€80.00View Rating Details
11/8/2017Deutsche BankSet Price TargetBuy€90.00View Rating Details
11/8/2017Oddo BhfSet Price TargetBuy€90.00View Rating Details
11/8/2017J P Morgan Chase & CoSet Price TargetBuy€85.00View Rating Details
11/7/2017CommerzbankSet Price TargetBuy€76.00View Rating Details
(Data available from 12/11/2015 forward)

Earnings

Earnings History for Morphosys (ETR:MOR)


No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Morphosys (ETR:MOR) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Morphosys (ETR:MOR)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Morphosys (ETR MOR)

No insider trades for this company have been tracked by MarketBeat.com

Headlines

Morphosys (ETR MOR) News Headlines

Source:
DateHeadline
Morphosys (MOR) PT Set at €85.00 by Berenberg BankMorphosys (MOR) PT Set at €85.00 by Berenberg Bank
www.americanbankingnews.com - December 7 at 9:56 PM
BRIEF-Morphosys Says Licensee Janssen Receives Approval For Tremfya In CanadaBRIEF-Morphosys Says Licensee Janssen Receives Approval For Tremfya In Canada
www.reuters.com - December 6 at 9:08 AM
MorphoSys to Host Investor & Analyst Call On December 12, 2017 About Data On MOR208 Presented at the 2017 ASH Annual MeetingMorphoSys to Host Investor & Analyst Call On December 12, 2017 About Data On MOR208 Presented at the 2017 ASH Annual Meeting
finance.yahoo.com - December 5 at 5:44 PM
MorphoSys: Janssen Receives Approval For Tremfya In Canada - Quick Facts - NasdaqMorphoSys: Janssen Receives Approval For Tremfya In Canada - Quick Facts - Nasdaq
www.nasdaq.com - December 5 at 9:21 AM
I-Mab Biopharma Partners with MorphoSys on Cancer Investigational MedicineI-Mab Biopharma Partners with MorphoSys on Cancer Investigational Medicine
www.bizjournals.com - December 2 at 10:20 AM
MorphoSys AG: MorphoSys Signs Regional License Agreement for Antibody MOR202 with I-MabMorphoSys AG: MorphoSys Signs Regional License Agreement for Antibody MOR202 with I-Mab
www.finanznachrichten.de - November 30 at 9:08 AM
MorphoSys Announces Licensing Agreement For MOR202; Increases GuidanceMorphoSys Announces Licensing Agreement For MOR202; Increases Guidance
www.rttnews.com - November 30 at 9:08 AM
Ad Hoc: MorphoSys Increases Financial Guidance for 2017 Following Signature of Regional License Agreement for Antibody MOR202 with I-MabAd Hoc: MorphoSys Increases Financial Guidance for 2017 Following Signature of Regional License Agreement for Antibody MOR202 with I-Mab
finance.yahoo.com - November 30 at 9:08 AM
MorphoSys Signs Regional License Agreement for Antibody MOR202 with I-MabMorphoSys Signs Regional License Agreement for Antibody MOR202 with I-Mab
finance.yahoo.com - November 30 at 9:08 AM
Morphosys AG (MOR) PT Set at €80.00 by Goldman Sachs Group IncMorphosys AG (MOR) PT Set at €80.00 by Goldman Sachs Group Inc
www.americanbankingnews.com - November 27 at 10:32 PM
MorphoSys: Janssen Receives Market Authorization For Tremfya In ... - NasdaqMorphoSys: Janssen Receives Market Authorization For Tremfya In ... - Nasdaq
www.nasdaq.com - November 23 at 5:19 PM
MorphoSys Announces That Its Licensee Janssen Has Received Approval for Tremfya(R) (Guselkumab) in Europe for the Treatment of Moderate-to-Severe Plaque PsoriasisMorphoSys Announces That Its Licensee Janssen Has Received Approval for Tremfya(R) (Guselkumab) in Europe for the Treatment of Moderate-to-Severe Plaque Psoriasis
finance.yahoo.com - November 23 at 5:19 PM
MorphoSys AG (MOR) Receives Consensus Rating of "Buy" from AnalystsMorphoSys AG (MOR) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - November 19 at 9:50 AM
Top 4 Inexpensive Healthcare Mutual Funds for 2018Top 4 Inexpensive Healthcare Mutual Funds for 2018
www.zacks.com - November 15 at 6:28 AM
MorphoSys AG 2017 Q3 - Results - Earnings Call SlidesMorphoSys AG 2017 Q3 - Results - Earnings Call Slides
seekingalpha.com - November 8 at 9:02 PM
MorphoSys Announces Third Quarter 2017 Results - Baystreet.caMorphoSys Announces Third Quarter 2017 Results - Baystreet.ca
www.baystreet.ca - November 8 at 3:58 PM
MorphoSys Q3 Loss Widens, Revenues Up; Backs FY17 View - Quick Facts - NasdaqMorphoSys Q3 Loss Widens, Revenues Up; Backs FY17 View - Quick Facts - Nasdaq
www.nasdaq.com - November 8 at 3:58 PM
MorphoSys AG (MOR) Given a €85.00 Price Target by Berenberg Bank AnalystsMorphoSys AG (MOR) Given a €85.00 Price Target by Berenberg Bank Analysts
www.americanbankingnews.com - November 7 at 11:23 AM
MorphoSys AG: MorphoSys Announces Third Quarter 2017 ResultsMorphoSys AG: MorphoSys Announces Third Quarter 2017 Results
www.finanznachrichten.de - November 7 at 6:59 AM
MorphoSys Announces Third Quarter 2017 ResultsMorphoSys Announces Third Quarter 2017 Results
finance.yahoo.com - November 7 at 6:59 AM
MorphoSys Announces Presentation of Clinical Data...MorphoSys Announces Presentation of Clinical Data...
www.benzinga.com - November 2 at 6:30 AM
MorphoSys Announces Presentation of Clinical Data on Proprietary Blood Cancer Compound MOR208 at Upcoming American Society of Hematology Annual Meeting 2017MorphoSys Announces Presentation of Clinical Data on Proprietary Blood Cancer Compound MOR208 at Upcoming American Society of Hematology Annual Meeting 2017
finance.yahoo.com - November 2 at 6:29 AM
MorphoSys AG (MOR) Earns Buy Rating from J P Morgan Chase & CoMorphoSys AG (MOR) Earns Buy Rating from J P Morgan Chase & Co
www.americanbankingnews.com - November 2 at 6:22 AM
Berenberg Bank Analysts Give MorphoSys AG (MOR) a €85.00 Price TargetBerenberg Bank Analysts Give MorphoSys AG (MOR) a €85.00 Price Target
www.americanbankingnews.com - November 1 at 2:23 PM
Dr. Markus Enzelberger Appointed MorphoSyss Chief Scientific OfficerDr. Markus Enzelberger Appointed MorphoSys's Chief Scientific Officer
finance.yahoo.com - October 31 at 6:29 AM
MorphoSys AG (MOR) PT Set at €90.00 by Deutsche Bank AGMorphoSys AG (MOR) PT Set at €90.00 by Deutsche Bank AG
www.americanbankingnews.com - October 30 at 11:52 AM
MorphoSys to Host Q3 2017 Conference Call on November 7, 2017MorphoSys to Host Q3 2017 Conference Call on November 7, 2017
finance.yahoo.com - October 27 at 8:02 AM
MorphoSys AG (MOR) Given a €81.00 Price Target by Oddo Bhf AnalystsMorphoSys AG (MOR) Given a €81.00 Price Target by Oddo Bhf Analysts
www.americanbankingnews.com - October 26 at 7:11 AM
MorphoSys AG (MOR) Given Average Recommendation of "Buy" by AnalystsMorphoSys AG (MOR) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - October 25 at 10:45 AM
MorphoSys AG: MorphoSys Receives FDA Breakthrough Therapy Designation for Its Antibody MOR208 in Relapsed/Refractory DLBCLMorphoSys AG: MorphoSys Receives FDA Breakthrough Therapy Designation for Its Antibody MOR208 in Relapsed/Refractory DLBCL
www.finanznachrichten.de - October 25 at 7:35 AM
BRIEF-Morphosys says received FDA breakthrough therapy designation for its antibody MOR208 in Relapsed/Refractory DLBCLBRIEF-Morphosys says received FDA breakthrough therapy designation for its antibody MOR208 in Relapsed/Refractory DLBCL
www.reuters.com - October 24 at 6:37 AM
MorphoSys AG (MOR) Given a €85.00 Price Target at Berenberg BankMorphoSys AG (MOR) Given a €85.00 Price Target at Berenberg Bank
www.americanbankingnews.com - October 22 at 11:04 PM
J P Morgan Chase & Co Analysts Give MorphoSys AG (MOR) a €85.00 Price TargetJ P Morgan Chase & Co Analysts Give MorphoSys AG (MOR) a €85.00 Price Target
www.americanbankingnews.com - October 7 at 7:26 PM
MorphoSys AG (MOR) Given a €84.00 Price Target by Independent Research GmbH AnalystsMorphoSys AG (MOR) Given a €84.00 Price Target by Independent Research GmbH Analysts
www.americanbankingnews.com - October 4 at 12:06 PM
Sorrento Therapeutics (SRNE) Names Dorman Followwill & Dave Lemus to BoardSorrento Therapeutics (SRNE) Names Dorman Followwill & Dave Lemus to Board
www.streetinsider.com - October 2 at 11:42 AM
Sorrento Therapeutics (SRNE) Names Dorman Followwill & Dave Lemus to BoardSorrento Therapeutics (SRNE) Names Dorman Followwill & Dave Lemus to Board
www.streetinsider.com - October 2 at 11:42 AM
MorphoSys AG (MOR) Given a €76.00 Price Target by Commerzbank Ag AnalystsMorphoSys AG (MOR) Given a €76.00 Price Target by Commerzbank Ag Analysts
www.americanbankingnews.com - October 1 at 9:52 AM
MorphoSys AG (MOR) Given a €72.00 Price Target by Goldman Sachs Group, Inc. (The) AnalystsMorphoSys AG (MOR) Given a €72.00 Price Target by Goldman Sachs Group, Inc. (The) Analysts
www.americanbankingnews.com - September 30 at 6:00 PM
MorphoSys AG (MOR) Given Consensus Recommendation of "Buy" by BrokeragesMorphoSys AG (MOR) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - September 30 at 10:40 AM
Galapagos and MorphoSys report first promising signs of clinical activity in a Phase 1 study with IL-17C antibody ... - GlobeNewswire (press release)Galapagos and MorphoSys report first promising signs of clinical activity in a Phase 1 study with IL-17C antibody ... - GlobeNewswire (press release)
globenewswire.com - September 27 at 9:32 AM
MorphoSys and Galapagos Report First Promising Signs of Clinical Activity in a Phase 1 Study With IL-17C-Antibody MOR106 in Atopic Dermatitis PatientsMorphoSys and Galapagos Report First Promising Signs of Clinical Activity in a Phase 1 Study With IL-17C-Antibody MOR106 in Atopic Dermatitis Patients
finance.yahoo.com - September 27 at 9:32 AM
Goldman Sachs Group, Inc. (The) Reiterates €55.00 Price Target for MorphoSys AG (MOR)Goldman Sachs Group, Inc. (The) Reiterates €55.00 Price Target for MorphoSys AG (MOR)
www.americanbankingnews.com - September 24 at 8:32 PM
Berenberg Bank Analysts Give MorphoSys AG (MOR) a €68.00 Price TargetBerenberg Bank Analysts Give MorphoSys AG (MOR) a €68.00 Price Target
www.americanbankingnews.com - September 24 at 1:32 PM
MorphoSys Announces That Its Licensee Janssen Has Initiated Two Phase 3 Studies with Tremfya(TM) (Guselkumab ... - Baystreet.caMorphoSys Announces That Its Licensee Janssen Has Initiated Two Phase 3 Studies with Tremfya(TM) (Guselkumab ... - Baystreet.ca
www.baystreet.ca - September 23 at 8:19 AM
MorphoSys Announces That Its Licensee Janssen Has Initiated Two Phase 3 Studies with Tremfya(TM) (Guselkumab) in Psoriatic ArthritisMorphoSys Announces That Its Licensee Janssen Has Initiated Two Phase 3 Studies with Tremfya(TM) (Guselkumab) in Psoriatic Arthritis
finance.yahoo.com - September 22 at 6:23 AM
MorphoSys AG: MorphoSys Announces that its Licensee Janssen received CHMP Positive Opinion for Tremfya (Guselkumab) Recommending Approval in EuropeMorphoSys AG: MorphoSys Announces that its Licensee Janssen received CHMP Positive Opinion for Tremfya (Guselkumab) Recommending Approval in Europe
www.finanznachrichten.de - September 19 at 4:13 AM
MorphoSys Announces that its Licensee Janssen received CHMP Positive Opinion for Tremfya(TM) (Guselkumab) Recommending Approval in EuropeMorphoSys Announces that its Licensee Janssen received CHMP Positive Opinion for Tremfya(TM) (Guselkumab) Recommending Approval in Europe
finance.yahoo.com - September 18 at 5:56 AM
MorphoSys AG (MOR) Stock Rating Reaffirmed by J P Morgan Chase & CoMorphoSys AG (MOR) Stock Rating Reaffirmed by J P Morgan Chase & Co
www.americanbankingnews.com - September 10 at 8:52 PM
MorphoSys AG (MOR) Given a €55.00 Price Target by Goldman Sachs Group, Inc. (The) AnalystsMorphoSys AG (MOR) Given a €55.00 Price Target by Goldman Sachs Group, Inc. (The) Analysts
www.americanbankingnews.com - September 10 at 3:16 PM
MorphoSys AG (MOR) Given a €77.00 Price Target at Independent Research GmbHMorphoSys AG (MOR) Given a €77.00 Price Target at Independent Research GmbH
www.americanbankingnews.com - September 7 at 7:18 AM

SEC Filings

Morphosys (ETR:MOR) SEC Filings

DateFilerForm TypeView

Social Media

Social activity is not available for this stock.

Financials

Financials are not available for this stock.

Chart

Morphosys (ETR MOR) Stock Chart for Monday, December, 11, 2017

Loading chart…

This page was last updated on 12/11/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.